Sterile water for injection 2 ml vial

Injectable Collagen
Hydrolysate - 1 btl 4 mg

BIOTECK S.p.A.
Headquarters:
Via E. Fermi 49 - 36057 Arcugnano (VI) - Italy
ph: +39 0444 289366 - fax +39 0444 285272
info@bioteck.com - www.bioteck.com

Production and R&D Center:
Via G. Agnelli, 3 - 10020 Riva presso Chieri (TO) - Italy

Accessory kit for CHondroGrid® application (not included)

Inject the solution into the articular space, if necessary under instrumental guidance, such as echography, especially when treating hip and shoulder.

INTRA-ARTICULAR INJECTION
Three injections administered over a period of 45 days:
first at day 1, second at day 15, third at day 45.

Injectable Hydrolyzed Collagen
Code CHG-004
Injectable Collagen
Hydrolysate - 1 btl 4 mg

The most innovative and advanced method of treating chondropathies
CHondroGrid® is a locally-acting medical device that makes hydrolyzed collagen low-molecular weight peptides immediately available at the site of interest, and allows effective treatment of pain and loss of functionality caused by articular affections.

**HYDROLYZED COLLAGEN**

Collagen is the main component of all intra-articular structures. Therefore, when joints are injected with hydrolyzed collagen, a mixture of low-molecular weight peptides, these small molecules actively prompt the reparation and reinforcement of the articular matrix and they also help the recovery and preservation of the native trophic state of all the joint compartments.

CHondroGrid® consists of 4 mg of hydrolyzed peptides with a molecular weight lower than 3kDa. After being suspended in injectable water, and consequently delivered to the patient by intra-articular injection, they spread rapidly all over the articular surface.

CHondroGrid® targets directly the suffering site, delivering small collagen-specific amino acid chains that will support the structural and functional recovery of the intra-articular components. As a consequence, articular pain and function improve.

CHondroGrid®, therefore, may help reducing analgesics and NSAIDs.

**Indications**

The most common indications for the use of CHondroGrid® are the symptoms, management, and functional treatment of: osteoarthritis, acute or chronic arthrosynovitis secondary to osteoarthritis or rheumatoid arthritis, traumas or injuries, articular overload and overwork.

CHondroGrid® is also indicated in cases of degenerative meniscopathies, prior to and following meniscectomy surgery, or cleaning following meniscectomy surgery, or cleaning.

**Effectiveness**

Hydrolyzed collagen is absolutely non cytotoxic. Instead, in vitro experiments show it increases all parameters measuring cell vitality (1), (4). No immunogenic effects have ever been observed in vivo (5). It has been shown to be effective on degenerative articular disorders both in preclinical and clinical studies published in international, peer-reviewed journals (6), (7), (8), (9). Such studies include double-blind randomized clinical trials on patients affected by knee osteoarthritis (10), (11).

**Safety and Performance**

**TSE-related Safety**

CHondroGrid® is manufactured starting from Pharma-grade highly purified bovine collagen. The extraction process applied to purify the CHondroGrid® bovine collagen has been certified safe by the European Directorate for the Quality of Medicines (EDQM) as far as the TSE (Transmissible Spongiform Encephalopathies) risk is concerned. During its production, Biotech further checks the raw material for the absence of prions using biomolecular assays, such as Western Blot Test and HPLC chromatography. Safety and performance assessments performed on the CHondroGrid® device have been validated by all the Member States of the European Community.**

**Biological Safety**

Biotech performs strict microbiological tests on each product batch and monitors, along the entire production line, all the environments where the device is manufactured and packaged. After packaging, the product is sterilized by beta irradiation at a 25 kGy dose. The irradiation preserves all the qualitative and quantitative features of the peptide profile, causing no decay of the device performance. HPLC data recorded before and after sterilization show that the chromatographic profiles fully overlap, as shown in the plot that follows.